The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.CEO Albert Bourla ...

Markets today face key jobs data, fresh U.S. tariffs, and earnings from Wendy’s, AMC Networks, and other midcaps ahead of the ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

XAU/USD consolidates above the 50-day MA, as softer U.S. data boosts rate cut odds. Gold price future hinges on inflation and ...

Second Quarter 2025 Results Key Financial Results Revenue: US$14.7b (up 10% from 2Q 2024).

The issuer is solely responsible for the content of this announcement.

AstraZeneca, which last week announced a $50bn plan for US development, declined to comment. Pfizer, Abbvie, and Germany’s ...

New data highlights an unprecedented crisis in National Health Service patient waiting lists and sheds light on how the ...

Research and development expenses fell 48.2% compared to Q2 2024, while general and administrative costs rose 121.1%, Research and development expenses were $1.0 million compared to $2.1 million for ...